AOD-9604
MetabolicEndocrine and metabolic applications of AOD-9604 span direct incretin-axis engagement, AMPK and mitochondrial signalling, and adiposity-driven inflammation. A modified human growth hormone fragment studied for fat metabolism without the growth-promoting side effects of full GH. The ~30 min IV; longer SubQ pharmacokinetic profile and subq/oral (capsule, lower bioavailability) administration shape the rate at which glycemic markers move; the typical AOD-9604 effect window in metabolic syndrome populations is 8-12 weeks.
Key Takeaways
Metabolic lens: AOD-9604 is tracked against glycemic, insulin sensitivity, visceral adiposity, and inflammatory markers. Mechanism: Mimics the C-terminal of human growth hormone (residues 176-191) to stimulate lipolysis and inhibit lipogenesis via β3-adrenergic-like signalling, without engaging the GH receptor or driving IGF-1 elevation. Metabolic monitoring: baseline HbA1c, fasting glucose, fasting insulin, HOMA-IR, hsCRP, ALT/AST; ideally CGM in first cycle. Metabolic dose: 300-500 mcg 1x daily am via subq/oral (capsule, lower bioavailability). Metabolic-medicine stack partners: Semaglutide (GLP-1), Cagrilintide, MOTS-c.
Mimics the C-terminal of human growth hormone (residues 176-191) to stimulate lipolysis and inhibit lipogenesis via β3-adrenergic-like signalling, without engaging the GH receptor or driving IGF-1 elevation. Metabolic implications: how the mechanism interacts with insulin signalling, AMPK and mitochondrial biogenesis, visceral adiposity, and the appetite circuit. AOD-9604's contribution at each layer is examined in the subsections below, with reference to the clinical biomarkers (HbA1c, fasting insulin, HOMA-IR, hsCRP, ALT/AST) that track each.
Visceral fat and the cardiometabolic axis
AOD-9604's effect on visceral adipose tissue, hepatic steatosis, and cardiometabolic risk indices is the dimension most clinically tracked. Visceral fat is one of the more responsive endpoints for this class. The most-tracked markers are waist circumference, ALT/AST (hepatic), hsCRP (inflammation), and — where available — DEXA-quantified visceral fat.
Weight management and the appetite circuit
Direct appetite effects are not the principal mechanism, but downstream effects on inflammation and metabolic flexibility translate into sustainable rather than rapid weight management. Pairing with adequate protein intake and resistance training is the standard approach for users targeting weight reduction.
Insulin signalling and glycemic effect
AOD-9604's relationship to insulin signalling is one of the central practical considerations. Direct incretin-axis effects are limited, but downstream insulin sensitivity is influenced through inflammatory, mitochondrial, or weight-related mechanisms. The implication for glycemic monitoring is clear: baseline HbA1c, fasting glucose, and — ideally — a CGM during the first cycle for users in or near the diabetes-spectrum range.
In the metabolic syndrome population, AOD-9604 for weight management produces measurable shifts on the cardiometabolic axis when paired with appropriate dietary and activity inputs. The compound's effect is additive to lifestyle rather than substitutive for it.
Where AOD-9604 is used for metabolic syndrome, integration with GLP-1 agonist therapy, AMPK activators, or visceral-fat-selective agents is the standard pattern in metabolic medicine clinics. Mono-therapy is appropriate for first-cycle users and for milder presentations.
AOD-9604 for insulin sensitivity is best-evaluated against baseline metabolic markers: fasting glucose, HbA1c, lipid panel, hsCRP, ALT/AST. Response timelines are typically 8–12 weeks for primary endpoints; secondary markers (inflammation, hepatic function) move on similar timescales.
In the metabolic syndrome population, AOD-9604 for gastric emptying produces measurable shifts on the cardiometabolic axis when paired with appropriate dietary and activity inputs. The compound's effect is additive to lifestyle rather than substitutive for it.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | 300-500 mcg | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | 180-500 mcg | 4–6 weeks initial cycle |
| Metabolic focus | SubQ | 300-500 mcg | 1x daily AM |
| Maintenance phase | SubQ | 210-500 mcg | Ongoing with periodic pauses |
Dose timing for AOD-9604 is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses. Fasted dosing produces stronger GH pulses; meal-paired dosing blunts the response.
AOD-9604 stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from metabolic medicine specialists.
- AOD-9604 + Semaglutide (GLP-1): Selective GLP-1 receptor agonist. Pairs naturally with AOD-9604's mechanism in metabolic / endocrine protocols.
- AOD-9604 + Cagrilintide: Selectively activates the amylin receptor (calcitonin receptor + RAMP1/3 complex). Pairs naturally with AOD-9604's mechanism in metabolic / endocrine protocols.
- AOD-9604 + MOTS-c: Translocates to the nucleus under metabolic stress and activates AMPK signalling. Pairs naturally with AOD-9604's mechanism in metabolic / endocrine protocols.
- AOD-9604 + Tesamorelin: Modified GHRH (1-44) sequence with an N-terminal trans-3-hexenoic acid that confers resistance to DPP-4 cleavage. Pairs naturally with AOD-9604's mechanism in metabolic / endocrine protocols.
No significant elevation of IGF-1, glucose, or insulin in trials. Generally well tolerated. Pregnancy/lactation: avoid (no data).
Lens-specific safety considerations for metabolic / endocrine use of AOD-9604: No significant elevation of IGF-1, glucose, or insulin in trials. Generally well tolerated. Pregnancy/lactation: avoid (no data). Additional metabolic / endocrine monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| AOD-9604 | GH fragment | ~30 min IV; longer SubQ | Metabolic |
| Semaglutide (GLP-1) | GLP-1 receptor agonist | ~7 days | The blockbuster GLP-1 receptor agonist with weekly dosing — engineered from native GLP-1 for protease resistance and albumin binding |
| Cagrilintide | Long-acting amylin analogue | ~7 days | A long-acting amylin analogue paired with semaglutide for weight loss results that exceed either drug alone |
| Tesamorelin | Stabilised GHRH analogue | ~30 min | An FDA-approved long-chain GHRH analogue used for HIV-associated lipodystrophy and notable for its consistent effect on visceral adipose reduction |
Is AOD-9604 appropriate alongside metformin or other diabetes medications?
Will I regain weight after stopping AOD-9604?
Will AOD-9604 affect my muscle mass during weight loss?
What weight loss can I expect?
How should AOD-9604 be stored and reconstituted?
Is AOD-9604 safe during pregnancy or breastfeeding?
Start a AOD-9604 Protocol
Alukard provides physician-supervised metabolic protocols with GMP-certified AOD-9604 and GMP-certified compounds with comprehensive metabolic and glycemic monitoring.
Get ProtocolQuick Facts
- Molecular weight
- 1815.1 Da
- Sequence length
- 16 aa
- Half-life
- ~30 min IV; longer SubQ
- WADA
- Not on prohibited list (verify annually)
- FDA
- Unapproved (Research Only)
- Research
- Phase IIb completed; not commercialised
Stack Partners
All metabolic / endocrine applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for AOD-9604 unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Metabolic / Endocrine Protocol for AOD-9604
Alukard provides physician-supervised metabolic protocols with GMP-certified compounds with comprehensive metabolic and glycemic monitoring.
HIPAA Compliant · GMP Certified · Physician Supervised